In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 8, 2003, Pages 1147-1154

  Márián, Teréz ^a   Szabó, Gábor ^a   Goda, Katalin ^a   Nagy, Henrietta ^a   Szincsák, Nóra ^a   Juhász, István ^a   Galuska, László ^a   Balkay, László ^a   Mikecz, Pál ^a   Trón, Lajos ^a   Krasznai, Zoltán ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

18FDG; 99mTc MIBI; 11C methionine; Multidrug resistance; P glycoprotein

Indexed keywords

ABC TRANSPORTER; FLUORODEOXYGLUCOSE F 18; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOLIGAND; TETROFOSMIN TC 99M; TRACER; VERAPAMIL;

ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG ACCUMULATION; DRUG EFFECT; DRUG UPTAKE; GAMMA RADIATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MULTIDRUG RESISTANCE; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; SCINTIGRAPHY; SCINTISCANNING; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CYCLOSPORINE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLUORODEOXYGLUCOSE F18; HUMANS; METABOLIC CLEARANCE RATE; MICE; MICE, SCID; P-GLYCOPROTEIN; RADIOISOTOPE DILUTION TECHNIQUE; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; VERAPAMIL;

EID: 10744223808     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1204-3     Document Type: Article

References (34)

1. Sharom FJ. The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 1997; 160:167-175.
2. Hendrikse NH, Franssren EJF, van der Graaf WTA, Vaalburg W, de Vries EGE. Visualization of multidrug resistance in vivo. Eur J Nucl Med 1999; 26:283-293.
3. Litman T, Druley TE, Stein DW, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001; 58:931-959.
4. Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets 2000; 1:85-99.
5. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001; 42:1007-1017.
6. Trock B, Leonessa JF, Clarke R. Multidrug resistance in breast cancer: a meta analyses of MDR1/Pgp 170 expression and its possible functional significance. J Natl Cancer Inst 1997; 89:917-931.
7. Simon SM, Schindler M. Cell biological mechanism of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994; 91:3497-3504.
8. Del Vecchio S, Ciarmiello A, Salvatore M. Clinical imaging of multidrug resistance in cancer. Q J Nucl Med 1999; 43:125-131.
9. 99mTc-MIBI imaging in patients with lung cancer. J Nucl Med 2001; 42:1476-1483.
10. Pauwels EKJ, McCready VR, Stoot JHMB, van Deurzen DFP. The mechanism of accumulation of tumour-localising radio-pharmaceuticals. Eur J Nucl Med 1998; 25:277-305.
11. De Moerloose B, Van der Wiele C, Dhooge C, Philippé J, Speleman F, Benoit Y, Laureys G, Dierckx RA. Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein. Eur J Nucl Med 1999; 26:396-403.
12. 99mTc-MIBI is a substrate for P-glycoprotein and the multidrug associated protein. Br J Cancer 1998; 77:9675-9682.
13. Kostakoglu L, Kiratli P, Ruacan S, Hayran M, Emri S, Ergün EL, Bekdik CF. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med 1998; 39:228-234.
14. Goda K, Balkay L, Márián T, Trón L, Aszalós A, Szabó G Jr. Intracellular pH does not affect drug extrusion by P-glycoprotein. J Photochem Photobiol B: Biol 1996; 34:177-182.
15. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 1992; 267:4854-4858.
16. Mankoff DA, Bellon JR. Positron-emission tomographic imaging of cancer: glucose metabolism and beyond. Semin Radiat Oncol 2001; 11:16-27.
17. Wahl LR. Targeting glucose transporters for tumor imaging: "sweet" idea, "sour" result. J Nucl Med 1996; 37:1038-1041.
18. Jager P, Vaalburg W, Pruim J, de Vries E, Langen K, Piers A. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001; 42:432-445.
19. Shen DW, Cardarelli C, Hwang J, Cornwell MM, Richert N, Ishii S, Pastan I, Gottesman MM. Multiple drug-resistant human KB carcinoma cells independently selected for high level resistance to colchicines, adriamycine or vinblastine show changes in expression of specific proteins. J Biol Chem 1986; 261:7762-7770.
20. 18F)-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235-238.
21. 11C] labeled methyl iodide using aqueous HI adsorbed on alumina. Radiochim Acta 1997; 76:197-201.
22. Márián T, Balkay L, Krasznai Z, Trón L. Membrane permeability changes induce hyperpolarization in transformed lymphoid cells under high density culture conditions. Cytometry 2000; 41:186-192.
23. Barbics E, Kronauge JF, Cohen D, Davison A, Jones AG, Croop JM. Characterization of P-glycoprotein transport and inhibition in vivo. Cancer Res 1998; 58:276-282.
24. m-tetrofosmin in human breast cancer and soft tissue sarcoma cell lines. Nucl Med Commun 2001; 22:645-650.
25. m-sestamibi. J Nucl Med 1994; 35:510-515.
26. 3H-daunomycin uptake in human carcinoma cells: relation to the MDR phenotype and effects of reversing agents. J Nucl Med 1999; 40: 672-676.
27. Broxterman HJ, Pinedo HM, Kuiper CM, Schuurhuis GJ, Lankelma J. Glycolysis in P-glycoprotein-overexpressing human tumor cell lines. Effects of resistance-modifying agents. FEBS Lett 1989; 247:405-410.
28. Broxterman HJ, Pinedo HM, Schuurhuis GJ, Lankelma J. Cyclosporin A and verapamil have different effects on energy metabolism in multidrug-resistant tumour cells. Br J Cancer 1990; 62:85-88.
29. Nagy H, Goda K, Arceci R, Cianfriglia M, Mechetner E, Szabó G Jr. P-glycoprotein conformational changes detected by antibody competition. Eur J Biochem 2001; 268:2416-2420.
30. Goda G, Nagy H, Mechetner E, Cianfriglia M, Szabó G Jr. Effects of ATP depletion and phosphate analogues on P-glycoprotein conformation in live cells. Eur J Biochem 2001; 269:2672-2677.
31. Utsunomiya K, Ballinger JR, Piquette-Miller M, Rauth AM, Tang W, Su Zi-Fen, Ichise M. Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line. Eur J Nucl Med 2000; 27:1786-1792.
32. Rybczynska M, Liu R, Lu P, Sharom FJ, Steinfels E, Di Pietro A, Spitaler M, Grunicke H, Hofmann J. MDR1 causes resistance to the antitumour drug miltefosine. Br J Cancer 2001; 84:1405-1411.
33. Schuldes H, Doleres J, Zimmer G, Knobloch J, Bickeboller R, Jonas D, Woodcock BG. Reversal of multidrug resistance and increase in plasma membrane fluidity in CHO cells with R-verapamil and bile salts. Eur J Cancer 2001; 37: 670-667.
34. Lu P, Liu R, Sharom FJ. Drug transport by reconstituted P-glycoprotein in proteoliposomes. Effect of substrates and modulators, and dependence on bilayer phase state. Eur J Biochem 2001; 268:1687-1697.